AptarGroup
Designs dispensing, drug-delivery, closure, and material-science solutions.
Something off on this page? Send us feedback.
Profile
Designs dispensing and protection systems for pharmaceutical and consumer products through Pharma, Beauty, and Closures. Drug delivery, pumps, closures, and active material-science solutions serve global end markets.
Designs and manufactures drug-delivery systems, dispensing pumps, aerosol valves, closures, and active material-science solutions. These systems shape how medicines and consumer products are delivered, sealed, and protected. Its technology roots include aerosol valves, spray pumps, and molded dispensing closures. Aptar Pharma serves prescription drugs, consumer health care, injectables, and digital-health-related services; Aptar Beauty serves beauty, personal care, and home care; Aptar Closures serves food, beverage, personal care, home care, beauty, and health care.
Operations span 20 countries, and the business builds capabilities through bolt-on acquisitions, particularly in Pharma. Growth and integration depend on executing acquisitions and operating within regulated environments.
Company facts
Categories
Key statistics
Year to date +8.5% · Average volume (30d) 441.8K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | Raymond James | Reiterate | Outperform | $160 | ||
| Mar 20, 2026 | Wells Fargo | Upgrade | Equal Weight | Overweight | ||
| Feb 9, 2026 | Robert W. Baird | Target | $145 | $156 | ||
| Jan 9, 2026 | KeyBanc | Target | $220 | |||
| Jan 6, 2026 | Wells Fargo | Downgrade | Overweight | Equal Weight |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $1.35 | $1.42 | +5.2% | $1.01B | $1.03B | +1.7% | +0.07% |
| Apr 30, 2026Q1 FY26 | $1.15 | $1.19 | +3.5% | $956.0M | $982.9M | +2.8% | −3.77% |
| Feb 5, 2026Q4 FY25 | $1.24 | $1.25 | +0.8% | $878.6M | $962.7M | +9.6% | +8.33% |
| Oct 30, 2025Q3 FY25 | $1.57 | $1.62 | +3.2% | $880.2M | $961.1M | +9.2% | −6.71% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $887.3M | $966.0M | $961.1M | $962.7M | $982.9M | $1.03B | |
| Gross profit | $270.8M | $297.1M | $287.9M | $261.6M | $276.2M | $285.9M | |
| Operating income | $115.5M | $146.0M | $139.1M | $110.7M | $108.6M | $128.1M | |
| Net income | $78.8M | $111.7M | $127.9M | $74.3M | $72.7M | $87.6M | |
| Diluted EPS | $1.17 | $1.67 | $1.92 | $1.13 | $1.12 | $1.36 | |
| Gross margin | 30.5% | 30.8% | 29.9% | 27.2% | 28.1% | 27.8% | |
| Operating margin | 13.0% | 15.1% | 14.5% | 11.5% | 11.1% | 12.5% |
Fiscal years (4-quarter sums)FY21 $3.23B · FY22 $3.32B · FY23 $3.49B · FY24 $3.58B · FY25 $3.78B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $197.3M · Total debt $1.43B · Total assets $5.13B · Shareholders' equity $2.63B
Dividends
Raised for 31 straight years — most recently to $0.48 from $0.45 in Oct 2025. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 30, 2026 | Jul 30 | Aug 20 | $0.48 | |
| May 6, 2026 | May 6 | May 27 | $0.48 | |
| Feb 4, 2026 | Feb 4 | Feb 25 | $0.48 | |
| Oct 23, 2025 | Oct 23 | Nov 13 | $0.48 | raised from $0.45 |
| Jul 24, 2025 | Jul 24 | Aug 14 | $0.45 | |
| May 1, 2025 | May 1 | May 22 | $0.45 | |
| Feb 5, 2025 | Feb 5 | Feb 26 | $0.45 | |
| Oct 24, 2024 | Oct 24 | Nov 14 | $0.45 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 63.82M · Float 62.95M · 98.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 6.14M | 9.62% | 13F | Aug 7, 2026 |
| State Farm Mutual Automobile Insurance Co | 4.74M | 7.43% | 13F | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 3.64M | 5.70% | 13F | Aug 13, 2026 |
| Morgan Stanley | 3.52M | 5.52% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 2.89M | 4.53% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | Gael Touya | officer: Segment Pres., CEO Designate | −3,740 | $133.76 |
| Aug 4, 2026 | Marc Prieur | officer: Segment President | −3,500 | $136.26 |
| Aug 3, 2026 | Stephan B. Tanda | director, officer: President and CEO | −9,838 | $136.16 |
| Aug 3, 2026 | Hedi Tlili | officer: Segment President | −8,854 | $135.00 |
| Jun 9, 2026 | Marc Prieur | officer: Segment President | −5,000 | $115.58 |
Peers
- West Pharmaceutical Services
Injectable-drug containment and delivery systems
- Stevanato Group
Drug containment and delivery for pharma and biotech
- Silgan
Dispensing and specialty closures across consumer end markets
- TriMas
Specialty closures and dispensing systems for consumer packaging
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AptarGroup | $132.99 | −0.02% | $8.49B | 24.0 | 22.4 | 2.2 | +6.3% |
| West Pharmaceutical Services | $349.58 | +3.61% | $23.75B | 43.2 | 36.5 | 7.1 | +13.9% |
| Stevanato Group | $21.15 | +0.33% | $5.74B | 37.8 | 26.6 | 4.1 | +4.6% |
| Silgan | $42.10 | −0.02% | $4.45B | 16.6 | 10.8 | 0.7 | +6.8% |
| TriMas | $39.53 | +0.01% | $1.42B | 1.6 | 20.1 | 1.8 | −36.5% |
| Median | 27.2 | 23.4 | 3.0 | +5.7% |